Annals of Hematology

, 90:1153

Hodgkin’s lymphoma—long-term outcome: an experience from a tertiary care cancer center in North India

  • Prasanth Ganesan
  • Lalit Kumar
  • Vinod Raina
  • Atul Sharma
  • Sameer Bakhshi
  • Vishnubhatla Sreenivas
  • Malini Vijayaraghavan
  • Sanjay Thulkar
Original Article


Limited information is available from developing countries on long-term outcome of patients with Hodgkin’s lymphoma (HL). Between January 1998 and December 2005, 262 patients (age ≥15 years) underwent treatment. Patients’ median age was 30 years, ranging from 15 to 72 years. Male to female ratio was 2.8:1. B symptoms were present in 64% of patients. Seventy percent of patients had stage III and IV disease. Mixed cellularity (52.3%) was the most common histology followed by nodular sclerosis (38%). ABVD chemotherapy was used in 85% of the patients, and 50% received radiotherapy as consolidation. Following treatment 92% of patients achieved complete response. Five-year freedom from treatment failure (FFTF) and overall survival rate are 78.3% and 86.6% ± 0.02% (95% CI 80.0–93.2%), respectively. Stage at presentation, number of lymph node regions involved (≥3 vs ≤2), presence of B symptoms, and serum albumin (≥40 vs <40 g/L) were important determinants of FFTF. In a subset analysis of stage I and II HL patients, presence of bulky disease and pure infradiaphragmatic disease was associated with inferior outcome. On multivariate analysis involvement of three or more number of lymph node regions was a significant predictor of inferior freedom from treatment failure survival (hazard ratio 2.2, p < 0.01). Our analysis confirms excellent outcome for patients of Hodgkin’s lymphoma with results comparable to developed countries.


Hodgkin’s lymphoma Developing countries Outcome Survival Prognostic factors 


  1. 1.
    Bonadonna G (2000) Historical review of Hodgkin’s disease. Br J Haematol 110:504–511PubMedCrossRefGoogle Scholar
  2. 2.
    Diehl V, Thomas RK, Daniel R (2004) Hodgkin’s lymphoma—diagnosis and treatment (part II). Lancet Oncol 5(1):19–26PubMedCrossRefGoogle Scholar
  3. 3.
    Armitage JO (2010) Early-stage Hodgkin’s lymphoma. NEJM 363:653–662PubMedCrossRefGoogle Scholar
  4. 4.
    Kuruvilla J, Keating A, Crump M (2011) How I treat relapsed and refractory Hodgkin lymphoma? Blood 117(16):4208–4217PubMedCrossRefGoogle Scholar
  5. 5.
    Shanta V, Sastri DV, Sagar TG, Sasikala K, Krishnamurthi S (1982) A review of Hodgkin’s disease at the Cancer Institute, Madras. Clin Oncol 8(1):5–15PubMedGoogle Scholar
  6. 6.
    Dinshaw K, Pande S, Advani SH, Ramakrishnan G et al (1985) Pediatric Hodgkin’s disease in India. J Clin Oncol 3:1605–1612PubMedGoogle Scholar
  7. 7.
    Chandi L, Kumar L, Kochupillai V, Dawar R, Singh R (1998) Hodgkin’s disease: a retrospective analysis of 15 years experience at a large referral center. Natl Med J India 11:212–217PubMedGoogle Scholar
  8. 8.
    Arya LS, Dinand V, Thavaraj V, Bakhshi S, Dawar R, Rath GK, Singh R, Vats TS (2006) Hodgkin’s disease in Indian children: outcome with chemotherapy alone. Pediatr Blood Cancer 46:26–34PubMedCrossRefGoogle Scholar
  9. 9.
    Raina V, Sharma A, Mohanti BK, Kumar R, Dawar R, Rath GK (2003) Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin’s disease. Natl Med J India 16:199–203PubMedGoogle Scholar
  10. 10.
    Laskar S, Gupta T, Vimal S et al (2004) Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 22:62–68PubMedCrossRefGoogle Scholar
  11. 11.
    Lister TA, Crowther D, Sutcliffe SB et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7:1630–1636PubMedGoogle Scholar
  12. 12.
    Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. IARC Press, LyonGoogle Scholar
  13. 13.
    Kumar L, Malik PS, Prakash G, Prabu R, Radhakrishnan V, Kayal S, Hariprasad R (2011) Autologous hematopoietic stem cell transplantation—what determines the outcome: an experience from North India. Ann Hematol. doi:10.1007/s00277-011-1205-4
  14. 14.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting the results of cancer treatment. Cancer 47:207–211PubMedCrossRefGoogle Scholar
  15. 15.
    Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339:1506–1514PubMedCrossRefGoogle Scholar
  16. 16.
    Mauch PM, Kalish LA, Kadin M, Coleman CN, Osteen R, Hellman S (1993) Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer 71(6):2062–2071PubMedCrossRefGoogle Scholar
  17. 17.
    Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al. (2009) SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. Bethesda, MD. Based on November 2008 SEER data submission, posted to the SEER web site, 2009. Accessed 21 Mar 2010
  18. 18.
    Vassallo J, Paes RP, Soares FA et al (2005) Histological classification of 1,025 cases of Hodgkin’s lymphoma from the State of São Paulo, Brazil. São Paulo Med J 123:134–136PubMedGoogle Scholar
  19. 19.
    Cheong JW, Park SY, Roh JK, Suh CO, Hahn JS (2006) Treatment of Hodgkin’s disease: a twenty-year follow-up of patients at a center in Korea. Yonsei Med J 47:455–465PubMedCrossRefGoogle Scholar
  20. 20.
    Dinand V, Dawar R, Arya LS, Unni RS, Mohanty B, Singh R (2007) Hodgkin’s lymphoma in Indian children: prevalence and significance of Epstein–Barr virus detection in Hodgkin’s and Reed–Sternberg cells. Eur J Cancer 43:161–168PubMedCrossRefGoogle Scholar
  21. 21.
    Karnik BS, Nair S (2003) Hodgkin’s lymphoma: immunohistochemical features and its association with EBV LMP-1. Experience from a South Indian hospital. Pathology 35:207–211PubMedCrossRefGoogle Scholar
  22. 22.
    Glaser SL, Hsu JL (2002) Hodgkin’s disease in Asians: incidence patterns and risk factors in population-based data. Leuk Res 26:261–269PubMedCrossRefGoogle Scholar
  23. 23.
    Allemani C, Sant M, De Angelis R, Marcos-Gragera R, Coebergh JW (2006) EUROCARE Working Group. Hodgkin disease survival in Europe and the U.S.: prognostic significance of morphologic groups. Cancer 107:352–360PubMedCrossRefGoogle Scholar
  24. 24.
    Brenner H, Gondos A, Pulte D (2009) Survival expectations of patients diagnosed with Hodgkin’s lymphoma in 2006–2010. Oncologist 14:806–813PubMedCrossRefGoogle Scholar
  25. 25.
    Brenner H, Gondos A, Pulte D (2008) Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 111:2977–2983PubMedCrossRefGoogle Scholar
  26. 26.
    Verdecchia A, Francisci S, Brenner H et al (2007) EUROCARE-4 Working Group. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol 8:784–796PubMedCrossRefGoogle Scholar
  27. 27.
    Eichenauer DA, Bredenfeld H, Haverkamp H, Müller H, Franklin J, Fuchs M et al (2009) Hodgkin’s lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin Study Group. J Clin Oncol 27:6079–6085PubMedCrossRefGoogle Scholar
  28. 28.
    Specht L, Nissen NI (1988) Hodgkin’s disease stages I and II with infradiaphragmatic presentation: a rare and prognostically unfavourable combination. Eur J Haematol 40(5):396–402PubMedCrossRefGoogle Scholar
  29. 29.
    Darabi K, Sieber M, Chaitowitz M, Braitman LE, Tester W, Diehl V et al (2005) Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1,114 patients. Leuk Lymphoma 46(12):1715–1720PubMedCrossRefGoogle Scholar
  30. 30.
    Gerhartz HH, Beykirch M, Hitter E, Wilmanns W (1993) Chemotherapy dose and survival in advanced Hodgkin’s disease. Acta Haematol 89:137–140PubMedCrossRefGoogle Scholar
  31. 31.
    Evens AM, Cilley J, Ortiz T et al (2007) G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 137(6):545–552PubMedCrossRefGoogle Scholar
  32. 32.
    Boleti E, Mead GM (2007) ABVD for Hodgkin’s lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 18(2):376–380PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Prasanth Ganesan
    • 1
  • Lalit Kumar
    • 1
  • Vinod Raina
    • 1
  • Atul Sharma
    • 1
  • Sameer Bakhshi
    • 1
  • Vishnubhatla Sreenivas
    • 2
  • Malini Vijayaraghavan
    • 3
  • Sanjay Thulkar
    • 4
  1. 1.Department of Medical OncologyAll India Institute of Medical SciencesNew DelhiIndia
  2. 2.Department of BiostatisticsAll India Institute of Medical SciencesNew DelhiIndia
  3. 3.Department of PathologyAll India Institute of Medical SciencesNew DelhiIndia
  4. 4.Department of RadiodiagnosisAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations